ALK and non-small cell lung carcinoma: There are currently four US Food and Drug Administration–approved ALK inhibitors for the treatment of NSCLC: crizotinib (Xalkori), ceritinib (Zykadia), alectinib (Alecensa), and brigatinib (Alunbrig).